Supplemental Medicines-Nutritions Used by Health Personnel in their own Covid-19 Treatment Schedule

Abstract

ABSTRACT OBJECTIVE. İn this study, with a view to investigate drug use behaviors of healthcare personnels who had Covid 19 infection in the first 1 year of the pandemic, it was aimed to determine the additional drugs and nutritional supplements they used in their own treatment. MATERIAL METHOD This is a descriptive cross-sectional study. The data were obtained through an online survey voluntarily completed under pandemic conditions by doctors, dentists, nurses, pharmacists and other health personnel who declared that they had Covid-19. RESULTS The study consisted of 405 individuals. 98% of healthcare personnels preferred to support their treatment. The medicines and herbal products that the participants started to use by their own decisions, without the advice of the physician who examined them, and the frequency of their use were vitamin C 53.3%, vitamin D 48.1%, acetylsalicylic acid 26.7%, paracetamol 23%, zinc 26.4%, multivitamin 19%, acetylcysteine 14.8%, famotidine 14.3%, subcutaneous heparin 12.6%. As for herbal products, inhaling thyme oil was noted in 11.6%, drinking thyme oil 10.1%, consuming ginger 14.3% of the participants. Non-prescription support products were found to be beneficial in 44.4%. CONCLUSION Almost all of the participants took a supplement with an intention to support the treatment. The fact that one out of two participants declared that they benefited from over-the-counter supplements reveals that further studies are needed to support the rational use of over-the-counter products in the treatment of Covid 19.

Keywords

• Covid 19
• Healthcare Personnale
• Medicine
• Herbal products
• Nutritions

References

1. REFERENCES 1. WHO. 04.04.2021]; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
2. 2. Webpage. [cited 31.03.2021; Available from: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdUOA?Si.
3. 3. BOZKURT, Y., Z. ZEYBEK, and R. AŞKIN, Covid-19 pandemisi: Psikolojik etkileri ve terapötik müdahaleler. İstanbul Ticaret Üniversitesi Sosyal Bilimler Dergisi, 2020. 19(37): p. 304-318.
4. 4. Reperant, L.A. and A. Osterhaus, AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? Vaccine, 2017. 35(35 Pt A): p. 4470-4474.
5. 5. GÜNAY, E., Klinisyen Gözüyle COVİD-19 Tedavisi. 2020.
6. 6. Weppage. 2021; Available from: https://tr.euronews.com/2021/06/03/hangi-ulkede-kac-kisiye-covid-19-as-s-yap-ld.
7. 7. Xu, X., Y.K. Ong, and Y. Wang, Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Mil Med Res, 2020. 7(1): p. 22.
8. 8. Şeker, M., et al., Covid-19 Pandemi Değerlendirme Raporu. Türkiye Bilimler Akademisi, 2020.

9. 9. Bohlken, J., et al., [COVID-19 Pandemic: Stress Experience of Healthcare Workers - A Short Current Review]. Psychiatr Prax, 2020. 47(4): p. 190-197.
10. 10. Pappa, S., et al., Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav Immun, 2020. 88: p. 901-907.
11. 11. WHO. 2021 15.04.2021]; Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210202_weekly_epi_update_25.pdf.
12. 12. Lahner, E., et al., Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy. International Journal of Environmental Research and Public Health, 2020. 17(12): p. 4417.
13. 13. Bebitoğlu, B.T., et al., Klorokin/Hidroksiklorokin: COVID-19 tedavisi ile gündeme gelen eski bir ilaca farmakolojik bakış. Anadolu Kliniği Tıp Bilimleri Dergisi, 2020. 25(Special Issue on COVID 19): p. 204-215.
14. 14. Gautret, P., et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020. 56(1): p. 105949. 15. Ramireddy, A., et al., Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc, 2020. 9(12): p. e017144.
15. 16. Pan, H., et al., Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med, 2021. 384(6): p. 497-511.
16. 17. Webpage. 2021 [cited 2021 01.06.2021]; Available from: https://covid19.saglik.gov.tr/Eklenti/40719/0/covid-19rehberieriskinhastayonetimivetedavipdf.pdf.
17. 18. Shannon, A., et al., Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nature communications, 2020. 11(1): p. 1-9.
18. 19. Doi, Y., et al., A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrob Agents Chemother, 2020. 64(12).
19. 20. Shiraki, K. and T. Daikoku, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & therapeutics, 2020. 209: p. 107512.
20. 21. Doi, K., et al., Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Critical Care, 2020. 24(1): p. 1-4.
21. 22. Udwadia, Z.F., et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis, 2021. 103: p. 62-71.
22. 23. Shrestha, D.B., et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virology Journal, 2020. 17(1): p. 141.
23. 24. Khamis, F., et al., Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis, 2021. 102: p. 538-543.
24. 25. Ye, Z., et al., Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. Canadian Medical Association Journal, 2020. 192(20): p. E536-E545.
25. 26. Indari, O., et al., An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come? Front Pharmacol, 2021. 12: p. 632677.
26. 27. Humeniuk, R., et al., Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Clin Transl Sci, 2020. 13(5): p. 896-906.
27. 28. Langford, B.J., et al., Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical Microbiology and Infection, 2020. 26(12): p. 1622-1629.
28. 29. Amundstuen Reppe, L., O. Spigset, and J. Schjøtt, Drug Information Services Today: Current Role and Future Perspectives in Rational Drug Therapy. Clin Ther, 2016. 38(2): p. 414-21.
29. 30. ÇAKIR, M. and M. ÇAKIR, COVID-19 HASTALARINDA KORTİKOSTEROİD TEDAVİSİ: NE ZAMAN VE NASIL? SDÜ Tıp Fakültesi Dergisi, (1): p. 197-208.
30. 31. Freedberg, D.E., et al., Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020. 159(3): p. 1129-1131.e3.
31. 32. Samimagham, H.R., et al., The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020. 21(1): p. 848.
32. 33. Xu, Z., et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine, 2020. 8(4): p. 420-422.
33. 34. Härtel, C., et al., Effects of vitamin C on intracytoplasmic cytokine production in human whole blood monocytes and lymphocytes. Cytokine, 2004. 27(4-5): p. 101-106.
34. 35. Liu, F., et al., Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. BMJ Open, 2020. 10(7): p. e039519.
35. 36. Carr, A.C., et al., Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Critical Care, 2017. 21(1): p. 1-10.
36. 37. Khan, H.M.W., et al., Unusual early recovery of a critical COVID-19 patient after administration of intravenous vitamin C. The American journal of case reports, 2020. 21: p. e925521-1.
37. 38. Cerullo, G., et al., The Long History of Vitamin C: From Prevention of the Common Cold to Potential Aid in the Treatment of COVID-19. Front Immunol, 2020. 11: p. 574029.
38. 39. Milani, G.P., M. Macchi, and A. Guz-Mark, Vitamin C in the Treatment of COVID-19. Nutrients, 2021. 13(4).
39. 40. Richardson, D.P. and J.A. Lovegrove, Nutritional status of micronutrients as a possible and modifiable risk factor for COVID-19: a UK perspective. Br J Nutr, 2021. 125(6): p. 678-684.
40. 41. Gröber, U. and M.F. Holick, The coronavirus disease (COVID-19) - A supportive approach with selected micronutrients. Int J Vitam Nutr Res, 2021: p. 1-22.